Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma

Jennifer M. Munson, Levi Fried, Sydney A. Rowson, Michael Y. Bonner, Lohitash Karumbaiah, Begoña Diaz, Sara Courtneidge, Ulla G. Knaus, Daniel J. Brat, Jack L. Arbiser, Ravi V. Bellamkonda

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The invasive nature of glioblastoma (GBM) represents a major clinical challenge contributing to poor outcomes. Invasion of GBM into healthy tissue restricts chemotherapeutic access and complicates surgical resection. Here, we test the hypothesis that an effective anti-invasive agent can "contain" GBM and increase the efficacy of chemotherapy. We report a new anti-invasive small molecule, Imipramine Blue (IB), which inhibits invasion of glioma in vitro when tested against several models. IB inhibits NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase-mediated reactive oxygen species generation and alters expression of actin regulatory elements. In vivo, liposomal IB (nano-IB) halts invasion of glioma, leading to a more compact tumor in an aggressively invasive RT2 syngeneic astrocytoma rodent model. When nano-IB therapy was followed by liposomal doxorubicin (nano-DXR) chemotherapy, the combination therapy prolonged survival compared to nano-IB or nano-DXR alone. Our data demonstrate that nano-IB-mediated containment of diffuse glioma enhanced the efficacy of nano-DXR chemotherapy, demonstrating the promise of an anti-invasive compound as an adjuvant treatment for glioma.

Original languageEnglish (US)
Article number127ra36
JournalScience Translational Medicine
Volume4
Issue number127
DOIs
StatePublished - Mar 28 2012
Externally publishedYes

Fingerprint

Imipramine
Glioma
Glioblastoma
Therapeutics
Drug Therapy
Astrocytoma
Combination Drug Therapy
NADP
Actins
Rodentia
Reactive Oxygen Species
Oxidoreductases
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Munson, J. M., Fried, L., Rowson, S. A., Bonner, M. Y., Karumbaiah, L., Diaz, B., ... Bellamkonda, R. V. (2012). Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Science Translational Medicine, 4(127), [127ra36]. https://doi.org/10.1126/scitranslmed.3003016

Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. / Munson, Jennifer M.; Fried, Levi; Rowson, Sydney A.; Bonner, Michael Y.; Karumbaiah, Lohitash; Diaz, Begoña; Courtneidge, Sara; Knaus, Ulla G.; Brat, Daniel J.; Arbiser, Jack L.; Bellamkonda, Ravi V.

In: Science Translational Medicine, Vol. 4, No. 127, 127ra36, 28.03.2012.

Research output: Contribution to journalArticle

Munson, JM, Fried, L, Rowson, SA, Bonner, MY, Karumbaiah, L, Diaz, B, Courtneidge, S, Knaus, UG, Brat, DJ, Arbiser, JL & Bellamkonda, RV 2012, 'Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma', Science Translational Medicine, vol. 4, no. 127, 127ra36. https://doi.org/10.1126/scitranslmed.3003016
Munson, Jennifer M. ; Fried, Levi ; Rowson, Sydney A. ; Bonner, Michael Y. ; Karumbaiah, Lohitash ; Diaz, Begoña ; Courtneidge, Sara ; Knaus, Ulla G. ; Brat, Daniel J. ; Arbiser, Jack L. ; Bellamkonda, Ravi V. / Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. In: Science Translational Medicine. 2012 ; Vol. 4, No. 127.
@article{d7af08b8cbb449b48fcd06407b5171bd,
title = "Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma",
abstract = "The invasive nature of glioblastoma (GBM) represents a major clinical challenge contributing to poor outcomes. Invasion of GBM into healthy tissue restricts chemotherapeutic access and complicates surgical resection. Here, we test the hypothesis that an effective anti-invasive agent can {"}contain{"} GBM and increase the efficacy of chemotherapy. We report a new anti-invasive small molecule, Imipramine Blue (IB), which inhibits invasion of glioma in vitro when tested against several models. IB inhibits NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase-mediated reactive oxygen species generation and alters expression of actin regulatory elements. In vivo, liposomal IB (nano-IB) halts invasion of glioma, leading to a more compact tumor in an aggressively invasive RT2 syngeneic astrocytoma rodent model. When nano-IB therapy was followed by liposomal doxorubicin (nano-DXR) chemotherapy, the combination therapy prolonged survival compared to nano-IB or nano-DXR alone. Our data demonstrate that nano-IB-mediated containment of diffuse glioma enhanced the efficacy of nano-DXR chemotherapy, demonstrating the promise of an anti-invasive compound as an adjuvant treatment for glioma.",
author = "Munson, {Jennifer M.} and Levi Fried and Rowson, {Sydney A.} and Bonner, {Michael Y.} and Lohitash Karumbaiah and Bego{\~n}a Diaz and Sara Courtneidge and Knaus, {Ulla G.} and Brat, {Daniel J.} and Arbiser, {Jack L.} and Bellamkonda, {Ravi V.}",
year = "2012",
month = "3",
day = "28",
doi = "10.1126/scitranslmed.3003016",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "127",

}

TY - JOUR

T1 - Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma

AU - Munson, Jennifer M.

AU - Fried, Levi

AU - Rowson, Sydney A.

AU - Bonner, Michael Y.

AU - Karumbaiah, Lohitash

AU - Diaz, Begoña

AU - Courtneidge, Sara

AU - Knaus, Ulla G.

AU - Brat, Daniel J.

AU - Arbiser, Jack L.

AU - Bellamkonda, Ravi V.

PY - 2012/3/28

Y1 - 2012/3/28

N2 - The invasive nature of glioblastoma (GBM) represents a major clinical challenge contributing to poor outcomes. Invasion of GBM into healthy tissue restricts chemotherapeutic access and complicates surgical resection. Here, we test the hypothesis that an effective anti-invasive agent can "contain" GBM and increase the efficacy of chemotherapy. We report a new anti-invasive small molecule, Imipramine Blue (IB), which inhibits invasion of glioma in vitro when tested against several models. IB inhibits NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase-mediated reactive oxygen species generation and alters expression of actin regulatory elements. In vivo, liposomal IB (nano-IB) halts invasion of glioma, leading to a more compact tumor in an aggressively invasive RT2 syngeneic astrocytoma rodent model. When nano-IB therapy was followed by liposomal doxorubicin (nano-DXR) chemotherapy, the combination therapy prolonged survival compared to nano-IB or nano-DXR alone. Our data demonstrate that nano-IB-mediated containment of diffuse glioma enhanced the efficacy of nano-DXR chemotherapy, demonstrating the promise of an anti-invasive compound as an adjuvant treatment for glioma.

AB - The invasive nature of glioblastoma (GBM) represents a major clinical challenge contributing to poor outcomes. Invasion of GBM into healthy tissue restricts chemotherapeutic access and complicates surgical resection. Here, we test the hypothesis that an effective anti-invasive agent can "contain" GBM and increase the efficacy of chemotherapy. We report a new anti-invasive small molecule, Imipramine Blue (IB), which inhibits invasion of glioma in vitro when tested against several models. IB inhibits NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase-mediated reactive oxygen species generation and alters expression of actin regulatory elements. In vivo, liposomal IB (nano-IB) halts invasion of glioma, leading to a more compact tumor in an aggressively invasive RT2 syngeneic astrocytoma rodent model. When nano-IB therapy was followed by liposomal doxorubicin (nano-DXR) chemotherapy, the combination therapy prolonged survival compared to nano-IB or nano-DXR alone. Our data demonstrate that nano-IB-mediated containment of diffuse glioma enhanced the efficacy of nano-DXR chemotherapy, demonstrating the promise of an anti-invasive compound as an adjuvant treatment for glioma.

UR - http://www.scopus.com/inward/record.url?scp=84859129495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859129495&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003016

DO - 10.1126/scitranslmed.3003016

M3 - Article

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 127

M1 - 127ra36

ER -